ALZN Stock Analysis: Buy, Sell, or Hold?
ALZN - Alzamend Neuro, Inc. Common Stock
$1.05
-0.45 (-30.00%)
▼
5d:
-42.62%
30d:
-49.52%
90d:
-48.28%
WAIT
LOW Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: Mar 09, 2026
0d
Get Alerted When ALZN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ALZN is down 42.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ALZN is down 42.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ALZN is currently trading at $1.05, which is considered oversold relative to its 30-day fair value range of $1.72 to $2.14.
Technical Outlook: Technically, ALZN is in a downtrend. The price is currently testing key support at $1.14. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 30.0% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $28.00 (+2566.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ALZN is in a downtrend. The price is currently testing key support at $1.14. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 30.0% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $28.00 (+2566.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$1.72 -
$2.14
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-30.0%)
- BULLISH: Trading 2566.7% below Wall St target ($28.00)
- WARNING: Recommendation downgraded due to -42.6% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$1.72 -
$2.14
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$1.14
Resistance Level
$2.36
Current Trend
Downtrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.40
Wall Street Target
$28.00
(+2566.7%)
Share & Embed Analysis
Last updated: March 30, 2026 8:26 AM ET
Data refreshes hourly during market hours. Next update: 9:26 AM
Data refreshes hourly during market hours. Next update: 9:26 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ALZN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
9
Sells
Net
INSIDERS SELLING
Recent Transactions
Milton C Ault III
SELL
1851 shares
2025-12-23
William B Horne
SELL
3333 shares
2025-12-19
Lynne Fahey Mcgrath
SELL
30 shares
2025-10-23
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 62 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$92 | 62 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$54 | 54 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 56 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 61 BUY |
